Bristol-Myers Squibb Company (BMY) |
|
78.28 -0.42 (-0.53%)
|
06-29 18:47 |
|
Open: |
78.7 |
Pre. Close: |
78.7 |
|
High:
|
79.17 |
Low:
|
77.99 |
|
Volume:
|
8,498,149 |
Market Cap:
|
166,663(M) |
|
|
|
|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
79.25 - 79.68 |
79.68 - 80.04 |
|
Low:
|
76.93 - 77.47 |
77.47 - 77.93 |
|
Close:
|
77.46 - 78.29 |
78.29 - 78.98 |
|
Technical analysis |
as of: 2022-06-29 4:51:53 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 94.12 One year: 109.94 |
| Support: |
Support1: 75.1 Support2: 71.7 |
| Resistance: |
Resistance1: 80.58 Resistance2: 94.12 |
| Pivot: |
75.82  |
| Moving Average: |
MA(5): 78.72 MA(20): 75.77
MA(100): 73.58 MA(250): 66.86 |
| MACD: |
MACD(12,26): 0.7 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 81.9  %D(3): 89.8 |
| RSI: |
RSI(14): 59.8 |
| 52-week: |
High: 80.58 Low: 53.22 |
| Average Vol(K): |
3-Month: 15,136 (K) 10-Days: 16,166 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BMY ] has closed below upper band by 24.4%. Bollinger Bands are 117.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 29 Jun 2022
Spire Wealth Management Sells 31537 Shares of Bristol-Myers Squibb (NYSE:BMY) - Defense World
Wed, 29 Jun 2022
Bristol Myers Squibb Stock: Downgrade To Hold Now (NYSE:BMY) - Seeking Alpha
Tue, 28 Jun 2022
BMY : Canada Approves OPDIVO For Treatment Of Certain Patients Diagnosed With Urothelial Cancer - Nasdaq
Mon, 27 Jun 2022
Bristol-Myers Squibb (BMY) Stock: Why It Increased 1.29% Today - Pulse 2.0
Mon, 27 Jun 2022
Bristol-Myers Squibb Company (NYSE:BMY) Stock Goes Ex-Dividend In Just Two Days - Yahoo Eurosport UK
Fri, 24 Jun 2022
Hot Stocks: Cruise stocks jump; CAMP plunges on earnings; BMY, LLY set 52-week highs - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
2,220 (M) |
| Shares Float |
2,170 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
78.1 (%) |
|
Shares Short
|
35,370 (K) |
|
Shares Short P.Month
|
47,340 (K) |
Stock Financials |
|
EPS
|
-2.43 |
|
EPS Est Next Qtl
|
0.79 |
|
EPS Est This Year
|
3 |
|
EPS Est Next Year
|
3.23 |
|
Book Value (p.s.)
|
16.76 |
|
Profit Margin (%)
|
13.3 |
|
Operating Margin (%)
|
22.1 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
5.1 |
|
Gross Profit (p.s.)
|
16.68 |
|
Sales Per Share
|
21.15 |
|
EBITDA (p.s.)
|
9.51 |
|
Qtrly Earnings Growth
|
-33.8 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-32.35 |
|
PEG Ratio
|
2.2 |
|
Price to Book value
|
4.67 |
|
Price to Sales
|
3.7 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2022-01-31 |
|
Ex-Dividend Date
|
2022-01-05 |
|
7 Binary Options
|
|
Your Ad Here
|
|
